Thyroid Hormone Receptor Beta protein complex in ER+ Breast Cancer
Conference Year
2023
Abstract
Breast cancer (BCa) is the most diagnosed cancer in women worldwide and the second leading cause of cancer death in the US. Estrogen receptor positive (ER+) BCa is characterized by tumor promoter estrogen receptor alpha (ERa), while our receptor of interest, Thyroid Hormone Receptor Beta (TRb), is a known tumor suppressor. TRb and ERa have several associated histone modifying proteins in common despite their differing actions. Through an investigation of protein-protein interactions, these complexes may change in the presence of hormone and synthetic hormone agonists. Their activity could amplify tumor suppression mediated by TRb to counteract the effects of ERa.
Primary Faculty Mentor Name
Frances Carr
Status
Undergraduate
Student College
College of Arts and Sciences
Second Student College
Patrick Leahy Honors College
Program/Major
Biochemistry
Primary Research Category
Life Sciences
Thyroid Hormone Receptor Beta protein complex in ER+ Breast Cancer
Breast cancer (BCa) is the most diagnosed cancer in women worldwide and the second leading cause of cancer death in the US. Estrogen receptor positive (ER+) BCa is characterized by tumor promoter estrogen receptor alpha (ERa), while our receptor of interest, Thyroid Hormone Receptor Beta (TRb), is a known tumor suppressor. TRb and ERa have several associated histone modifying proteins in common despite their differing actions. Through an investigation of protein-protein interactions, these complexes may change in the presence of hormone and synthetic hormone agonists. Their activity could amplify tumor suppression mediated by TRb to counteract the effects of ERa.